Cite
HARVARD Citation
Ritchlin, C. et al. (2019). Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 395 (10222), pp. 427-440. [Online].